CCR Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The NCI Center for Cancer Research (CCR) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 8 clinical trials at NIH that match your search criteria

Cancer by type/disease: Malignant Mesothelioma

Trial and Protocol Number Malignant Mesothelioma	Principal Investigator	Referral Contact
Phase I
A Phase IB Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination With Pemetrexed and Cisplatin as Front-line Therapy in Adults with Malignant Pleural Mesothelioma NCI-12-C-0170, NCT01675765	Raffit Hassan 301-451-8742	Yvonne Mallory 301-402-0255 malloryy@mail.nih.gov
A Pilot Study of Pentostatin Plus Cyclophosphamide Immune Depletion to Decrease Immunogenicity of SS1P in Patients With Mesothelioma NCI-11-C-0160, NCT01362790	Raffit Hassan 301-451-8742	Yvonne Mallory 301-402-0255 malloryy@mail.nih.gov

Trial and Protocol Number Lung Cancer	Principal Investigator	Referral Contact
Phase II
Phase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum NCI-12-C-0151, NCT01624090	David S. Schrump 301-496-2128	Tricia Kunst 301-451-1233 tricia_kunst@nih.gov
Phase I/II
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas NCI-10-C-0138, NCT01143545	David S. Schrump 301-496-2128	Tricia Kunst 301-451-1233 tricia_kunst@nih.gov
No Phase
Prospective Evaluation of Epigenetic Alterations in Patients With Thoracic Malignancies NCI-06-C-0014, NCT00447447	David S. Schrump 301-496-2128	Tricia Kunst 301-451-1233 tricia_kunst@nih.gov

Trial and Protocol Number Solid Tumor	Principal Investigator	Referral Contact
Phase I/II
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes NCI-12-C-0111, NCT01583686	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	June A. Kryk 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase I
An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of the Anti-mesothelin Antibody Drug Conjugate BAY94-9343 in Subjects With Advanced Solid Tumors NCI-12-C-0008, NCT01439152	Raffit Hassan 301-451-8742	Yvonne Mallory 301-402-0255 malloryy@mail.nih.gov
Phase 0
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers NCI-11-C-0212, NCT01413451	Raffit Hassan 301-451-8742	Yvonne Mallory 301-402-0255 malloryy@mail.nih.gov

For additional studies that may be appropriate for your disease type, please search under Solid Tumor.